Negative biomarkers such as TAMs, MDSc, CD4+ TRegs, B2M, HLA-A deletions and JAK1/2 mutations may decrease a cancer’s response to immunotherapy but are not used in clinical practice [21–23]. The gene discussed is CD4; the disease is cancer.